Clinical Trials Browser

Phase 1/2 × INDUSTRY × Androgen Receptor Antagonists × Clear all

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

Bites and Stings

NCT02987829 2021-04-23

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Phase 1/2 Completed

72 enrolled 19 charts

Adenocarcinoma